Cipla at PPFCF

From WebNotes, a public knowledge base. Last updated . Reading time ~11 min.

Lead

Cipla Limited is among the periodic pharmaceutical holdings of the Parag Parikh Flexi Cap Fund (PPFCF). The position has appeared in PPFCF factsheet portfolio listings across multiple cycles, alongside other healthcare holdings such as IPCA Laboratories at PPFCF.

The Cipla thesis combines several elements of the broader PPFAS investment philosophy. First, respiratory-leadership: Cipla is among the global leaders in respiratory generics, with a deep portfolio of metered-dose inhalers, dry-powder inhalers and other delivery systems. Its respiratory franchise has been a key competitive advantage in both India and key export markets including South Africa, Europe and increasingly the United States. Second, US generics scale: Cipla has built a meaningful US business with a portfolio of complex generics including respiratory generics, peptides and other niche products. Third, disciplined valuation-driven entry: the team has typically built or added to the position during cyclical compression windows.

The position is also a useful illustration of PPFAS value investing applied to a regulated and cyclical sector. Pharma faces periodic FDA inspection issues, pricing pressure in US generics and exchange-rate volatility on export revenues. PPFAS’s willingness to look through these cycles supports multi-period holding patterns and a PPFAS contrarian investing bias during sentiment troughs.

This article documents Cipla’s role in PPFCF: the company background, the investment thesis articulated by Rajeev Thakkar and Raunak Onkar (who tracks the pharma sector), the position history, recent positioning, and the comparison with peer holdings.

Company background

Cipla Limited (originally The Chemical, Industrial and Pharmaceutical Laboratories) was founded in 1935 by Khwaja Abdul Hamied in Mumbai. The company has played a pivotal role in Indian pharmaceutical history, including its decision in the early 2000s to manufacture and supply low-cost antiretroviral (ARV) drugs to treat HIV/AIDS in sub-Saharan Africa, a public-health intervention that significantly expanded access to treatment.

Cipla operates across India, North America, Europe, sub-Saharan Africa, South Africa, emerging markets and other geographies. The product portfolio spans respiratory (inhalers and nasal sprays), anti-infectives, urology, cardiovascular, central nervous system, gastrointestinal, oncology, dermatology and various other therapeutic areas. The company has a manufacturing footprint of more than 40 plants across India, South Africa and other geographies with various global regulatory approvals (US FDA, UK MHRA, WHO and others).

The company’s equity shares are listed on the National Stock Exchange and the Bombay Stock Exchange and are constituents of the Nifty 50 and the Sensex. The official corporate website is cipla.com. The registered office is at Mumbai Central, Mumbai.

For Indian retail investors, exposure to Cipla is straightforward through direct equity purchase on the NSE/BSE or through diversified equity mutual fund schemes. PPFCF’s exposure delivers indirect ownership through a SEBI Mutual Funds Regulations 1996 registered scheme.

Investment thesis at PPFCF

The PPFAS thesis on Cipla has been articulated across monthly factsheets and at the PPFAS Annual Unitholders Meet. The argument rests on several pillars.

First, PPFAS margin of safety. Cipla’s price-to-earnings multiple has compressed in cyclical periods (FDA inspection issues, US-generics pricing pressure, exchange-rate volatility), providing valuation-driven entry windows.

Second, respiratory franchise. Cipla’s respiratory portfolio (inhalers, nasal sprays, dry-powder devices) provides differentiated exposure with high entry barriers. Respiratory generics require complex device engineering, regulatory approvals and bioequivalence studies, which limit competitive entry.

Third, US generics scale. Cipla has built a US generics business focused on complex products rather than pure commodity generics. The pipeline includes respiratory generics (the generic version of GSK’s Advair Diskus was a key launch), peptides and other niche categories that offer higher margins than commodity generics.

Fourth, India formulations leadership. Cipla holds a strong position in the Indian Pharmaceutical Market (IPM) across multiple therapeutic areas, supported by a deep prescription-base and brand strength. The IPM has been a higher-margin and more stable end-market than US generics.

Fifth, balance-sheet quality. Cipla has historically maintained a manageable debt profile and generates positive free cash flow that supports R&D investment, capital expenditure and dividends.

Sixth, PPFAS focused portfolio discipline. Cipla meets the team’s quality bar through its respiratory franchise, India formulations strength and US-generics business.

Position history

Cipla has appeared in PPFCF disclosures across multiple periods. The position has been mentioned in PPFCF factsheet portfolio listings as one of the recurring Indian holdings within the pharmaceutical cluster, alongside IPCA Laboratories.

Through the 2018 to 2022 window the position fluctuated with pharma-sector cycles. US-generics pricing pressure was a recurring concern through 2018 to 2020 before easing somewhat. The COVID-19 pandemic provided a temporary tailwind for various respiratory and anti-infective products. The 2022 onwards period saw renewed strength in respiratory generics and complex products.

The February 2022 SEBI MF overseas investment cap freeze created a structural pivot in which domestic positions received continued allocations.

By 2025 and into 2026 the position continued as a periodic significant holding within the broader PPFCF portfolio, though it did not enter the top three (which by April 2026 was HDFC Bank at PPFCF, Power Grid Corporation at PPFCF and Coal India at PPFCF).

Recent positioning

The April 2026 factsheet, with PPFCF AUM at Rs 1,40,949 crore (up 9.29 per cent month-on-month from Rs 1,28,966 crore in March 2026), continued to include Cipla within the recurring domestic holdings list. The May 2026 commentary on PPFCF carrying around 18 to 22 per cent in PPFAS cash holdings reflected broader valuation caution.

In monthly factsheet commentary, Rajeev Thakkar and Raunak Onkar have referenced Cipla’s respiratory franchise, the US-generics pipeline and the India formulations strength as supports for continued holding.

Comparison with peer holdings

Within PPFCF’s pharmaceutical cluster, Cipla sits alongside IPCA Laboratories at PPFCF. Compared with IPCA, Cipla provides large-cap scale, broader US-generics exposure and higher respiratory-segment leverage. IPCA offers mid-cap operational beta with a different therapy-area mix (anti-malarials, pain, cardiovascular) and historical export-market emphasis.

Compared with ITC at PPFCF, Cipla offers different end-market exposure (regulated pharma versus FMCG and tobacco) and different regulatory complexity. Compared with the banking cluster (HDFC Bank, ICICI Bank, Kotak Mahindra Bank at PPFCF), Cipla provides healthcare exposure with export-revenue diversification.

Compared with international anchors Alphabet at PPFCF, Microsoft at PPFCF, Amazon at PPFCF and Meta Platforms at PPFCF, Cipla provides healthcare exposure that is uncorrelated with US-technology platform dynamics.

Within the broader PPFAS focused portfolio framework, Cipla is grouped with the banking cluster, the technology cluster, the consumer-discretionary cluster and the PSU contrarian positions as anchor Indian holdings.

Context within PPFCF

PPFCF was launched on 24 May 2013 as Parag Parikh Long Term Value Fund (PPLTVF), renamed Parag Parikh Long Term Equity Fund on 16 February 2018 and renamed Parag Parikh Flexi Cap Fund on 13 January 2021. The scheme is benchmarked against the Nifty 500 TRI and has delivered a compound annual growth rate since inception of approximately 19.06 per cent against a category average of 15.22 per cent and the Nifty 500 TRI at 12.4 per cent. AUM crossed Rs 1 lakh crore in May 2025, making PPFCF the first active equity mutual fund scheme in India to do so, and rose to roughly Rs 1.6 lakh crore by 15 May 2026.

The fund is managed by Rajeev Thakkar along with Raunak Onkar, Raj Mehta, Rukun Tarachandani and other team members. Parag Parikh, the founder of the Parag Parikh Financial Advisory Services Limited sponsor entity, established the investing house in 1979 and incorporated PPFAS Ltd in December 1992. The mutual fund was set up with SEBI on 10 October 2012 under registration ID MF/069/12/01.

Cipla has been a recurring topic at the PPFAS Annual Unitholders Meet. The 12th edition was held on 22 November 2025 at Birla Matushree Sabhaghar in Mumbai.

See also

External references

References

  1. PPFAS Mutual Fund, October 2025 factsheet, amc.ppfas.com.
  2. PPFAS Mutual Fund, March 2026 factsheet, amc.ppfas.com.
  3. INDmoney, “PPFAS Flexi Cap April 2026 portfolio update,” indmoney.com.
  4. Angel One, “Parag Parikh Flexi Cap Fund crosses one lakh crore AUM,” angelone.in.
  5. Business Today, May 2026 cash commentary, businesstoday.in.
  6. Cipla Limited, Annual Report 2024-25, cipla.com.
  7. Indian Pharmaceutical Alliance sector data.

Reviewed and published by

WebNotes Editorial Team

The WebNotes Editorial Team covers Indian capital markets, payments infrastructure and retail investor procedures. Every article is fact-checked against primary sources, principally SEBI circulars and master directions, NPCI specifications and the official support documentation published by the intermediary in question. Drafts go through a second-pair-of-eyes review and a separate compliance read before publication, and revisions are tracked against the SEBI and NPCI rule changes referenced in the methodology section.

Last reviewed
Conflicts of interest
WebNotes is independent. No relationship with any broker, registrar or bank named in this article.